Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2015 Sep 30.
Published in final edited form as: Psychiatry Res. 2014 Apr 26;219(1):198–203. doi: 10.1016/j.psychres.2014.04.031

Gender differences in oxytocin-associated disruption of decision bias during emotion perception

Spencer K Lynn a,1,*, Elizabeth A Hoge b,1, Laura E Fischer b, Lisa Feldman Barrett a,c, Naomi M Simon b
PMCID: PMC4086323  NIHMSID: NIHMS594790  PMID: 24814142

Abstract

Oxytocin is associated with differences in the perception of and response to socially mediated information, such as facial expressions. Across studies, however, oxytocin’s effect on emotion perception has been inconsistent. Outside the laboratory, emotion perception involves interpretation of perceptual uncertainty and assessment of behavioral risk. An account of these factors is largely missing from studies of oxytocin’s effect on emotion perception and might explain inconsistent results across studies. Of relevance, studies of oxytocin’s effect on learning and decision-making indicate that oxytocin attenuates risk aversion. We used the probability of encountering angry faces and the cost of misidentifying them as not angry to create a risky environment wherein bias to categorize faces as angry would maximize point earnings. Consistent with an underestimation of the factors creating risk (i.e., encounter rate and cost), men given oxytocin exhibited a worse (i.e., less liberal) response bias than men given placebo. Oxytocin did not influence women’s performance. These results suggest that oxytocin may impair men’s ability to adapt to changes in risk and uncertainty when introduced to novel or changing social environments. Because oxytocin also influences behavior in non-social realms, oxytocin pharmacotherapy could have unintended consequences (i.e., risk-prone decision-making) while nonetheless normalizing pathological social interaction.

Keywords: Signal detection theory, Face perception, Risk sensitivity, Behavioral economics

1. Introduction

Accumulating studies document changes in the perception of and response to socially mediated information, including emotion perceived from faces, associated with intranasal administration of oxytocin in humans (see meta-analyses by Van IJzendoorn and Bakermans-Kranenburg, 2012; Shahrestani et al., 2013). For example, Domes et al. (2007b) found that oxytocin increased men’s accuracy for difficult mental state attributions on the Reading the Mind in the Eyes task. Bartz et al. (2010) found that oxytocin rescued “empathic accuracy” of men who scored toward the high end of the normal range on the Autism Spectrum Quotient self-report questionnaire.

Although studies report oxytocin-associated increases in accuracy of facial emotion perception, there appears to be variation in the effect of oxytocin across different facial expressions. Guastella et al. (2008) found that oxytocin increased accuracy of men’s recall of previously seen faces depicting happiness but not angry or neutral faces. Marsh et al. (2010) found that oxytocin increased accuracy of men’s and women’s categorization of faces depicting happiness, but not anger, disgust, fear, sadness, or surprise. In contrast, however, Di Simplicio et al. (2009) reported that oxytocin increased accuracy of men’s categorization of neutral faces and depictions of surprise, but not of happiness. Similarly, Fischer-Shofty et al. (2010) found that oxytocin increased accuracy of men’s categorization of depictions of fear, but not of happiness. Lischke et al. (2012) found that oxytocin reduced the intensity of expression at which men identified depictions of angry and fearful faces but did not significantly affect accuracy of labeling faces as happy, angry, sad, or fearful. Thus, across studies the effects of oxytocin on emotion perception have been inconsistent (reviewed by Bartz et al., 2011; Graustella and MacLeod, 2012).

Generalizing across social cognition studies, oxytocin may improve the “salience” of social stimuli, and a variety of possible mechanisms have been identified including effects on initial stimulus appraisal, attention, behavioral motivation, and memory (see, e.g., Bartz et al., 2011; Kemp and Guastella, 2011; Churchland and Winkielman, 2012; Graustella and MacLeod, 2012). Individual differences, internal to the perceiver, and situational differences, such as aspects of study design, may account for some of the variation across emotion perception studies (Bartz et al., 2011; Graustella and MacLeod, 2012; Lischke et al., 2012).

Nonetheless, one consideration missing from studies of the effects of oxytocin on emotion perception is a characterization of emotion perception as a decision. Outside the laboratory, affective judgments about another person (e.g., Is that person angry at me? Do I trust that person?) involve interpretation of perceptual uncertainty (e.g., scowls do not always indicate anger) and assessment of behavioral risk (e.g., there are different costs to inferring an instance of anger when it does not exist, a “false alarm,” vs. missing an instance of anger when it does exist, a “missed detection”). Differences in the decision-like characteristics implemented by different study designs and analytic approaches could contribute to the apparent inconsistency of oxytocin’s effects. Although the results of emotion perception studies are often characterized as “improved” perception, generalization across studies or to perception outside the laboratory remains challenging. This difficulty arises, in part, because many studies have not sufficiently distinguished among various measures of performance, which include accuracy (proportion of trials answered correctly), conformation to a consensus norm, response bias, perceptual sensitivity, and decision optimality. For example, accuracy on the Reading the Minds in the Eyes task is a measure of congruence with a sample norm rather than a measure of performance over items that have objectively correct or incorrect answers (Baron-Cohen et al., 2001). Additionally, accuracy, even when it does reflect objective performance, is a function of sensitivity (ability to discriminate perceptual differences) and response bias (propensity to judge percepts as one alternative vs. another); high sensitivity and neutral bias both contribute to high accuracy (Macmillan and Creelman, 1991). Further, “accurate” perception (maximizing proportion correct) does not necessarily imply “optimal” perception (maximizing net benefit earned); it is the value earned from correct decisions, not the number of correct decisions, that is ultimately important. In environments where the costs of false alarm and missed detection differ, perceivers maximize net benefit by matching their behavior to the biased cost structure (Lynn et al., 2012), even though such bias can reduce accuracy.

In light of the inconsistencies in how emotion perception is conceptualized and measured, the results of oxytocin studies that utilize economic decision-making games may be relevant to understanding oxytocin’s effect on emotion perception. In the social economic “trust” game, “investors” decide how much money to transfer to a partner, the “trustee.” Trustees have the option to return the investment, with interest, or keep some or all of the investment and interest for themselves. Studies using the trust game indicate that oxytocin attenuates aversion to the risk of economic loss. Kosfeld et al. (2005) found that oxytocin increased the magnitude of men’s investments. Investors given oxytocin appeared less averse to the risk that their partner in the game might respond to the investment selfishly. Behavior between oxytocin and placebo groups did not differ in a non-social version of the game. Kosfeld et al. did not provide feedback to investors about whether or not trustees responded to the investment fairly or selfishly, indicating that the difference in “trust” was not based on learning from trial to trial.

Mikolajczak et al. (2010) directly manipulated men’s perception of risk in the trust game. While they found that oxytocin attenuated aversion to the risk of monetary loss, they also established a lower bound to the effect. Among men provided with vignettes (prior to the game) describing trustees as trustworthy, men given oxytocin made larger investments than those given placebo (replicating Kosfeld et al., 2005). However, men provided with vignettes describing trustees as untrustworthy invested little money, regardless of oxytocin treatment. This finding indicates that if risk is great enough, oxytocin does not noticeably alter risk perception.

Contrary to Kosfeld et al. (2005; see also Baumgartner et al., 2008), in a non-social version of the game, Mikolajczak et al. (2010) found that men who received oxytocin invested more than men who received placebo. Mikolajczak et al. (2010) showed that this “non-social” difference between studies lay in the different investment risk that participants inferred from the task instructions for the non-social game. Perception of economic risk may therefore be a salient domain of oxytocin’s activity, regardless of whether the risk has a social component.

Optimizing decisions (i.e., maximizing net benefit accrued over a series of decisions) involves learning from the outcomes of one’s past decisions. Baumgartner et al. (2008) found that oxytocin caused the magnitude of men’s investments in the trust game to remain unchanged following feedback that trustees had behaved selfishly. Men receiving placebo reduced their investment magnitude under the same conditions. Therefore, while the reduced risk aversion caused by oxytocin does not require feedback about the outcomes of one’s decisions in order to become established (Kosfeld et al., 2005), the reduction also appears immune to the consequences of poor decisions.

Although the results of studies utilizing this economic game are framed in the social terms of “trust” and risk of “betrayal,” more generally the economic loss resulting from poor decisions (e.g., the feedback provided by Baumgartner et al., 2008) may also be viewed as aversive feedback (i.e., punishment, as opposed to reward). Further evidence for a link between oxytocin and the perception of aversive feedback comes from a study utilizing aversive conditioning. Petrovic et al. (2008) initially elicited low ratings of how sympathetic individual faces appeared by pairing the faces with electric shock. Men who then received oxytocin (subsequent to the aversive conditioning) re-rated the faces as more sympathetic than did men who received placebo. Oxytocin, then, appears to reduce negatively valenced affective value associated with a stimulus, providing an explanation for why the effects of aversive feedback about one’s decisions are attenuated by oxytocin (i.e., Baumgartner et al., 2008).

Risk can be quantified with two parameters: estimated payoff value (e.g., magnitude of aversive feedback), and the estimated likelihood of accruing the payoff. Oxytocin may be decreasing either or both to bring about attenuated risk aversion. Although the two studies that involved aversive conditioning (Baumgartner et al., 2008; Petrovic et al., 2008) did not investigate oxytocin’s effects in these terms, a study of pain perception (Singer et al., 2008) may be relevant to understanding oxytocin’s effect on risk sensitivity. Singer et al. (2008) found that oxytocin reduced amygdala activation elicited by painful electric shock in men, which suggests that oxytocin may attenuate risk aversion by reducing the influence of negatively valent stimulation (e.g., the perceived relevance of aversive feedback), rather than the estimated likelihood of accruing the aversive feedback.

1.1 The current study

In sum, emotion perception may be viewed as a decision made under conditions of uncertainty and risk. Nonetheless, prior studies of emotion perception have not modeled this uncertainty and risk. Prior studies involving risk indicate that oxytocin attenuates risk aversion, but have not investigated emotion perception. Prior studies utilizing aversive stimulation and conditioning indicate that oxytocin’s influence on risk aversion could result from reducing the influence of aversive feedback on subsequent behavior. To bring together these elements and characterize oxytocin’s effects on emotion perception from a decision-making perspective, we utilized a task that combines perceptual uncertainty with behavioral economics in a signal detection framework (Lynn et al., 2012).

In signal detection theory, response bias is strongly influenced by the risk parameters, payoff magnitude and likelihood (Green and Swets, 1966). Achieving optimal bias requires that the perceiver accurately “estimate” these parameters and adjust (bias) his or her categorization behavior accordingly. We used the probability of encountering angry faces and the cost of misidentifying them as not angry to create a biased perceptual environment. We measured the effect of oxytocin on optimality of emotion perception bias in this environment.

Notably, almost all prior emotion perception studies of oxytocin from which our hypothesis has been drawn have examined men only. An exception is Domes et al. (2010), who studied women only. Domes et al. found, in an fMRI study, that for women, oxytocin-associated activity in the amygdala elicited by angry faces differed from that reported in prior studies of men. In women, oxytocin did not change amygdala activity in response to angry faces (Domes et al., 2010), while in men, oxytocin has led to reduced activity (e.g., Domes et al., 2007a). We included men and women in our sample but analyzed gender as a factor, in addition to oxytocin treatment condition.

Available data thus supported the hypothesis that men receiving oxytocin (vs. placebo) would under-estimate the cost of misidentifying angry faces as not angry and/or the probability of encountering angry faces (relative to not angry faces), such that oxytocin would be associated with a more neutral-going (suboptimal) bias when learning to judge scowling faces as angry or not. To explore the possibility that the effects of oxytocin on risky emotion perception decisions might differ by gender, we included gender as an analysis factor.

2. Methods

2.1 Participants & Procedure

Forty participants (age M=44.0 ± 10.32 [SD] years, 40% women, 75% Caucasian) free of psychiatric illness were recruited. Prior to administration of double blind oxytocin/placebo, participants received a medical screening (see Supplementary Material), and completed the first of three Affect Grids (Russell et al., 1989), a brief measure of affective state scored on dimensions of pleasure-displeasure and arousal-sleepiness. Under supervision, participants then self-administered 30 IU of double-blind intranasal oxytocin (10 sprays at 3 IU oxytocin per spray; Syntocinon®, Novartis Corporation) or placebo spray with a metered-dose pump actuator (oxytocin: n=22, 9 women; placebo: n=18, 7 women; see Supplementary Table S1).

Following drug/placebo administration, participants spent 25 minutes working on puzzles screened for neutral affective content to provide a standardized experience while waiting for the drug to be absorbed. After this period, participants completed a second Affect Grid and computer-based study tasks (see Supplementary Fig. S1). The emotion perception task described here started approximately 50 minutes after drug administration and lasted approximately 15 minutes. Finally, participants completed a third Affect Grid followed by additional self-report measures: the Positive and Negative Affect Scale (Watson et al., 1988), the Liebowitz Social Anxiety Scale (Heimberg et al., 1999), the Quick Inventory of Depressive Symptoms (Rush et al., 2003), the Perceived Stress Scale (Cohen et al., 1983), the State-Trait Anxiety Inventory (Spielberger et al., 1970), and an assessment of the treatment-blind to determine whether participants believed they took the active drug or placebo.

2.2 Emotion perception task

We designed a task to capture key features of uncertainty and risk inherent to emotion perception decisions. In social interactions, perceivers are faced with uncertainty about the state of a social partner. The uncertainty exists because, for example, sometimes people look angry when they are not (e.g., when they are concentrating), and sometimes people do not look angry when they in fact are (e.g., when they are hiding their emotions). In addition to uncertainty, the judgment (e.g., that the person is or is not angry) entails risk: The behavior of the perceiver, in light of his or her judgment, has consequences on subsequent social interactions. Benefits and costs accrue to the perceiver–for example, the social interaction may be facilitated or interrupted as a consequence of the perceiver’s judgment and subsequent actions (and in more extreme circumstances, the perceiver’s safety may be threatened). To capture these elements of uncertainty and risk in emotion perception, we used a computational, utility-based signal detection framework (Lynn et al., 2012). In this framework (Fig. 1), faces that depicted expressions ranging from relaxed to strongly scowling comprised two categories: “angry” (targets) and “not angry” (foils). Uncertainty was implemented by creating distributions of targets and foils that shared exemplars (i.e., the distributions overlapped on the perceptual domain). Targets were M = 60 ± 15% (1 SD) scowl intensity. Foils were M = 40 ± 15% (1 SD) scowl intensity. Risk was created by earning or losing points for correct vs. incorrect categorization of targets and foils. Correct detection (categorizing a target as “angry”) earned 10 points. Correct rejection (categorizing a foil as “not angry”) earned 10 points. Missed detection (categorizing a target as “not angry”) cost 10 points. False alarm (categorizing a foil as “angry”) cost 3 points. Additionally, the base rate of targets was 0.6 (60% of trials were targets). The combination of relatively high missed detection cost and relatively frequent targets dictated a liberal optimal bias (optimal c=−0.6 at maximum sensitivity of d′=1.33). That is, a tendency to categorize faces as angry was required to maximize points earned. Face stimuli comprised posed neutral and scowling expressions from 1 male and 1 female photographic model. We digitally blended the 0% scowling (neutral, relaxed-face) and 100% scowling faces of a given model to generate a series of 11 “morphs” that ranged from 0% to 100% scowling in 10% steps (Lynn et al., 2012; see also Supplementary Material).

Fig. 1.

Fig. 1

A utility-based signal detection framework for emotion perception. Three signal parameters (similarity of target [“angry”] and foil [“not angry”] signal distributions, decision payoffs [costs and benefits implemented as points earned or lost], and the base rate of occurrence of targets relative to foils) combine to yield a utility function (Lynn et al., 2012). The point of maximum utility locates the optimal decision criterion position (dashed drop line). Responding to faces of scowl intensity > criterion as “angry” will maximize net benefits accrued over a series of decisions (e.g., maximize points earned over trials). The left-of-center criterion location indicates a tendency to categorize faces as angry, called “liberal” response bias. The y-axis for the target and foil signal distributions (probability density) is not shown.

Over 230 trials, participants attempted to optimize their categorization of the faces, answering the on-screen prompt “Is this person angry?” by pressing keyboard buttons labeled “Yes” and “No”. Trials were presented on a computer monitor and began with a centered white fixation cross on a black screen (300 ms duration). Faces remained on-screen for 750 ms. The prompt followed the face, and remained on-screen until the participant’s response. Participants earned and lost points for correct or incorrect answers, and received immediate on-screen feedback (“Yes - that was right.” or “No - that was wrong.”, points earned for the current trial, and cumulative points earned). Following the feedback was a 300 ± 100 ms inter-trial interval (black screen).We recorded response button choice, points earned, and response time (from a USB keyboard) for each trial. Trials for which response times were less than 300 ms were excluded from analysis due to the high probability of their containing motor errors. We calculated bias (c), sensitivity (d′) (Macmillan and Creelman, 1991), and points earned on the remaining trials. Tasks were programmed in Matlab (The Mathworks, Inc.) with Psychophysics toolbox (version 3; Brainard, 1997). Stimulus set and response button location (left vs. right side of keyboard) were randomized across participants.

3. Results

We found associations between drug condition, response bias, and scores on the Perceived Stress Scale (PSS, which measures “stress” over the last month) and State-Trait Anxiety Inventory (Trait total score, STAI-T, which measures anxious tendencies “in general”), uncorrected for multiple comparisons across the other questionnaire scores and symptom assessments (Table 1). No such associations were found for the other affect questionnaires. Lacking pre-treatment ratings on the PSS and STAI-T scores, however, we could not distinguish possible effects of oxytocin on self-reported stress and anxiety from sampling differences at baseline. In light of the possibility of baseline differences in stress and anxiety between treatment groups, we evaluated the effect of oxytocin and gender on bias and sensitivity using PSS and STAI-T as covariates. The covariates did not interact significantly with the treatment and gender factors on bias or sensitivity outcomes, indicating that the covariates met the homogeneity of slopes assumption for Analysis of Covariance (ANCOVA).

Table 1.

Bias, sensitivity, stress, and anxiety scores (M ± 1 SD). PSS = Perceived Stress Scale, STAI-T = State Trait Anxiety Index–Trait Total.

Condition Bias (c) Sensitivity (d′) PSS1 STAI-T2 n
Oxytocin
 Male −0.09 ± 0.186 1.02 ± 0.219 9.2 ± 3.91 31.0 ± 4.93 13
 Female −0.20 ±0.179 0.99 ± 0.179 10.9 ± 5.86 31.6 ± 9.40 9
Placebo
 Male −0.29 ± 0.227 1.06 ± 0.362 8.0 ± 5.55 29.8 ± 6.57 11
 Female −0.15 ± 0.260 1.08 ± 0.178 6.0 ± 4.28 26.6 ± 4.08 7
1

PSS was marginally higher in the oxytocin group than in the placebo group (F(1,38)=2.9, p<0.098).

2

STAI-T was significantly correlated with bias in the oxytocin group (r=−0.44, p<0.041) but not in the placebo group (r=−0.31, p>0.2).

We found a significant interaction of treatment and gender on response bias (Table 1, Fig. 2; ANCOVA, F(1,32)=4.1, P<0.049, partial η2=0.11, power=0.51), without main effects, controlling for stress and anxiety in this non-psychiatrically ill sample. In line with our hypothesis, men who received oxytocin exhibited significantly less liberal (less optimal) bias than those who received placebo (follow-up ANCOVA among men, F(1,20)=5.0, P<0.037, partial η2=0.20, power=0.57). Women’s bias was not significantly affected by oxytocin (follow-up ANCOVA among women, F(1,12)=0.6, P>0.465, partial η2=0.04, power=0.11). Within each treatment group, bias of men and women did not differ significantly (follow-up ANCOVA among oxytocin group, F(1,22)=3.0, P>0.098, partial η2=0.14, power=0.38; follow-up ANCOVA among placebo group, F(1,18)=2.8, P>0.116, partial η2=0.17, power=0.35). There were no effects of treatment or gender on sensitivity.

Fig. 2.

Fig. 2

Men who received oxytocin exhibited significantly worse (less liberal-going) bias than those who received placebo. Women’s bias was not significantly affected by oxytocin. The y-axis is estimated marginal mean bias, controlling for stress and anxiety. Error bars show ± 1 SE. * indicates p<0.05.

4. Discussion

We hypothesized that oxytocin administration would be associated with insufficient decision bias in emotion perception in men. Consistent with this view, we found that men given oxytocin exhibited a relatively suboptimal (less liberal) response bias compared to men given placebo when participants attempted to optimize their decisions in response to experimenter-defined values of target-foil similarity, payoffs (points earned/lost), and “anger” base rate. Men given oxytocin appeared less able to calibrate their emotion perception to the signal detection parameters that cause bias (i.e., payoffs, base rate, or both). As a learning experiment, our results suggest that oxytocin may impair men’s ability to optimally adapt their emotion perception (e.g., judgments of angriness from faces) to differences in risk and uncertainty that characterize different social contexts.

We found no effect of oxytocin on women judging scowling faces as “angry” in our study. This result is congruent with studies showing no effect of oxytocin-associated activity in the amygdala elicited by angry faces in women (Domes et al., 2010) but reduced activity in men (e.g., Domes et al., 2007a). It is unlikely, however, that our null finding with faces depicting anger for women would generalize to all social perceptions. Domes et al. (2010), for example, did find that oxytocin increased women’s amygdala response to facial depictions of fear. Furthermore, although the literature is sparse, oxytocin-related differences in social perception between men and women appear to be varied. For example, Marsh et al. (2010) found that oxytocin increased accuracy for depictions of happiness in both men and women, while Fischer-Shofty et al. (2013) found that oxytocin increased accuracy for the perception of kinship in women but not men, and for the perception of competitive relationships in men but not women.

Our results point to a computational mechanism by which oxytocin could affect social approach–withdrawal motivation, which Kemp and Guastella (2011) used to characterize oxytocin’s effects in social and affective domains of experience. Namely, the increased social approach or reduced withdrawal motivation attributed to oxytocin may arise because events are perceived as less likely to be threats (reduced base rate), or if they are threats, less costly to endure (reduced missed detection cost).

We found that oxytocin impaired emotion perception under conditions requiring bias (i.e., requiring attention to costs and base rate). This result indicates one mechanism by which oxytocin produces the increased accuracy (i.e., proportion of trials responded to correctly) reported in prior emotion perception studies and supported by meta-analysis (Shahrestani et al., 2013). Emotion perception studies typically implement unbiased perceptual environments: the base rates of different emotion depictions are equal and any costs or benefits of categorizing a face as one emotion or another are not specified, so effectively equal. Participants bring their own idiosyncratic bias to any perceptual task (one impetus for the initial development of SDT; Green and Swets, 1966). Our results suggest that oxytocin could neutralize that bias to some extent, relative to placebo. Mathematically, neutral bias necessarily results in greater accuracy than liberal or conservative bias in unbiased environments (Supplementary Fig. S2). Thus, the neutralization of bias by oxytocin can explain the higher accuracy associated with oxytocin in neutrally-biased environments. Notably, in environments that demand non-neutral bias, such as the present study (and, we believe, many decisions outside the laboratory) unbiased decision-making is in fact suboptimal decision-making. Ultimately, it is not the number of correct decisions one makes (i.e., accuracy) that is important, but the balance of correct and incorrect decisions one achieves (i.e., bias), in light of their benefits and costs. Accuracy, as a tally of the number of correct and incorrect decisions, ignores the costs and benefits resulting from those decisions.

Oxytocin has been investigated as a pharmacological intervention in a variety of mental illnesses, including social anxiety disorder (Guastella et al., 2009), autism spectrum disorders (Guastella et al., 2010), and schizophrenia (Feifel et al., 2010); and disrupted oxytocin signaling has been implicated in post-partum depression (Feldman, 2012). Our results imply that oxytocin as an intervention may only be helpful to the extent that patients exhibit an overly-liberal threat detection bias, such as characterizes child abuse victims (Pollak and Kistler, 2002) and adults with social anxiety disorder (Gilboa-Schechtman et al., 2008), and in men only (at the dose administered here). Oxytocin might mitigate an overly-liberal threat detection bias by reducing estimates of the base rate of threat or reducing estimates of the magnitude of aversive feedback (costs), over-estimates of which could contribute to excessive social withdrawal or reduced social approach behaviors. However, if oxytocin’s effect is on the salience of aversive feedback but the patient’s impairment is better characterized as a base rate misperception, then treatment might show success (i.e., make an overly-liberal bias more neutral) for the wrong reason–modulation of perceived costs–which could potentially be problematic in the long-term.

In rodents, studies documenting oxytocin’s anxiolytic effects show its influence on behavioral decisions in non-social domains (e.g., Ring et al., 2006; Knobloch et al., 2012). If oxytocin also influences human decisions in non-social realms (e.g., Kirsch et al., 2005; Mikolajczak et al., 2010) then our results suggest that oxytocin pharmacotherapy could have unintended consequences, whatever its effects on emotion perception. For example, by inducing a devaluation of costs, oxytocin treatment could promote poor economic decisions or risk-prone behavior while nonetheless normalizing pathological social avoidance or mistrust.

A limitation of this study that must be addressed by future research is the difference in stress and anxiety ratings between the oxytocin and placebo groups (Table 1). It seems unlikely that the higher stress reported by oxytocin-participants was caused by the drug treatment; prior studies have reported no effects of oxytocin on self-reported mood, including anxiety and calmness (e.g., Kirsch et al., 2005; Domes et al., 2007a; Domes et al., 2007b; Baumgartner et al., 2008; Guastella et al., 2008; Di Simplicio et al., 2009; Bartz et al., 2010; Domes et al., 2010; Fischer-Shofty et al., 2010; Marsh et al., 2010). We controlled for the between-group difference statistically; nonetheless, a within-subjects design should be used in the future. With respect to the gender difference we report, a central limitation of this study is sample size. Power to further investigate the gender difference reported here would be enhanced by increased sample size.

Future directions for investigating the effects of oxytocin on the utility of emotion perception include studying facial expressions other than anger, and studying judgments that separate “threat” as part of the stimulus’ emotional meaning acquired prior to the experiment (e.g., an angry or fearful expression as a cue of potential threat) from the threat of making an incorrect decision (i.e., the punishment incurred by false alarms and missed detections). Further, based on prior studies of trust and aversive conditioning, we speculate that oxytocin may have reduced the salience of missed detection costs specifically. Systematic manipulations of all three signal detection parameters (similarity, payoffs, and base rate) could test this hypothesis.

Supplementary Material

01

Acknowledgments

We thank the members of the Interdisciplinary Affective Science Laboratory, Dept. Psychology, Northeastern University, for helpful feedback during the development of the manuscript. Preparation of this manuscript was supported by the Highland Street Foundation (Hoge, Simon, Fischer) and the National Institutes of Health (R01MH093394 to Lynn & Simon and DP1OD003312 to Barrett).

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

  1. Baron-Cohen S, Wheelwright S, Hill J, Raste Y, Plumb I. The “Reading the Mind in the Eyes” test revised version: a study with normal adults, and adults with Asperger syndrome or high-functioning autism. Journal of Child Psychology and Psychiatry. 2001;42:241–251. [PubMed] [Google Scholar]
  2. Bartz JA, Zaki J, Bolger N, Hollander E, Ludwig NN, Kolevzon A, Ochsner KN. Oxytocin selectively improves empathic accuracy. Psychological Science. 2010;21:1426–1428. doi: 10.1177/0956797610383439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bartz JA, Zaki J, Bolger N, Ochsner KN. Social effects of oxytocin in humans: context and person matter. Trends in Cognitive Sciences. 2011;15:301–309. doi: 10.1016/j.tics.2011.05.002. [DOI] [PubMed] [Google Scholar]
  4. Baumgartner T, Heinrichs M, Vonlanthen A, Fischbacher U, Fehr E. Oxytocin shapes the neural circuitry of trust and trust adaptation in humans. Neuron. 2008;58:639–650. doi: 10.1016/j.neuron.2008.04.009. [DOI] [PubMed] [Google Scholar]
  5. Brainard DH. The psychophysics toolbox. Spatial Vision. 1997;10:433–436. [PubMed] [Google Scholar]
  6. Churchland PS, Winkielman P. Modulating social behavior with oxytocin: how does it work? What does it mean? Hormones and Behavior. 2012;61:392–399. doi: 10.1016/j.yhbeh.2011.12.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. Journal of Health and Social Behavior. 1983;24:385–396. [PubMed] [Google Scholar]
  8. Di Simplicio M, Massey-Chase R, Cowen PJ, Harmer CJ. Oxytocin enhances processing of positive versus negative emotional information in healthy male volunteers. Journal of Psychopharmacology. 2009;23:241–248. doi: 10.1177/0269881108095705. [DOI] [PubMed] [Google Scholar]
  9. Domes G, Heinrichs M, Gläscher J, Büchel C, Braus DF, Herpertz SC. Oxytocin attenuates amygdala responses to emotional faces regardless of valence. Biological Psychiatry. 2007a;62:1187–1190. doi: 10.1016/j.biopsych.2007.03.025. [DOI] [PubMed] [Google Scholar]
  10. Domes G, Heinrichs M, Michel A, Berger C, Herpertz SC. Oxytocin improves ‘mind-reading’ in humans. Biological Psychiatry. 2007b;61:731–733. doi: 10.1016/j.biopsych.2006.07.015. [DOI] [PubMed] [Google Scholar]
  11. Domes G, Lischke A, Berger C, Grossmann A, Hauenstein K, Heinrichs M, Herpertz SC. Effects of intranasal oxytocin on emotional face processing in women. Psychoneuroendocrinology. 2010;35:83–93. doi: 10.1016/j.psyneuen.2009.06.016. [DOI] [PubMed] [Google Scholar]
  12. Feifel D, Macdonald K, Nguyen A, Cobb P, Warlan H, Galangue B, Minassian A, Becker O, Cooper J, Perry W, Lefebvre M, Gonzales J, Hadley A. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biological Psychiatry. 2010;68:678–680. doi: 10.1016/j.biopsych.2010.04.039. [DOI] [PubMed] [Google Scholar]
  13. Feldman R. Oxytocin and social affiliation in humans. Hormones and Behavior. 2012;61:380–391. doi: 10.1016/j.yhbeh.2012.01.008. [DOI] [PubMed] [Google Scholar]
  14. Fischer-Shofty M, Levkovitz Y, Shamay-Tsoory SG. Oxytocin facilitates accurate perception of competition in men and kinship in women. Social Cognitive and Affective Neuroscience. 2013;8:313–317. doi: 10.1093/scan/nsr100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Fischer-Shofty M, Shamay-Tsoory SG, Harari H, Levkovitz Y. The effect of intranasal administration of oxytocin on fear recognition. Neuropsychologia. 2010;48:179–184. doi: 10.1016/j.neuropsychologia.2009.09.003. [DOI] [PubMed] [Google Scholar]
  16. Gilboa-Schechtman E, Foa E, Vaknin Y, Marom S, Hermesh H. Interpersonal sensitivity and response bias in social phobia and depression: labeling emotional expressions. Cognitive Therapy and Research. 2008;32:605–618. [Google Scholar]
  17. Graustella AJ, MacLeod C. A critical review of the influence of oxytocin nasal spray on social cognition in humans: evidence and future directions. Hormones and Behavior. 2012;61:410–418. doi: 10.1016/j.yhbeh.2012.01.002. [DOI] [PubMed] [Google Scholar]
  18. Green DM, Swets JA. Signal Detection Theory and Psychophysics. Wiley; New York: 1966. [Google Scholar]
  19. Guastella AJ, Einfeld SL, Gray KM, Rinehart NJ, Tonge BJ, Lambert TJ, Hickie IB. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biological Psychiatry. 2010;67:692–694. doi: 10.1016/j.biopsych.2009.09.020. [DOI] [PubMed] [Google Scholar]
  20. Guastella AJ, Howard AL, Dadds MR, Mitchell P, Carson DS. A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder. Psychoneuroendocrinology. 2009;34:917–923. doi: 10.1016/j.psyneuen.2009.01.005. [DOI] [PubMed] [Google Scholar]
  21. Guastella AJ, Mitchell PB, Mathews F. Oxytocin enhances the encoding of positive social memories in humans. Biological Psychiatry. 2008;64:256–258. doi: 10.1016/j.biopsych.2008.02.008. [DOI] [PubMed] [Google Scholar]
  22. Heimberg RG, Horner KJ, Juster HR, Safren SA, Brown EJ, Schneier FR, Liebowitz MR. Psychometric properties of the Liebowitz Social Anxiety Scale. Psychological Medicine. 1999;29:199–212. doi: 10.1017/s0033291798007879. [DOI] [PubMed] [Google Scholar]
  23. Kemp AH, Guastella AJ. The role of oxytocin in human affect. Current Directions in Psychological Science. 2011;20:222–231. [Google Scholar]
  24. Kirsch P, Esslinger C, Chen Q, Mier D, Lis S, Siddhanti S, Gruppe H, Mattay VS, Gallhofer B, Meyer-Lindenberg A. Oxytocin modulates neural circuitry for social cognition and fear in humans. Journal of Neuroscience. 2005;25:11489–11493. doi: 10.1523/JNEUROSCI.3984-05.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Knobloch HS, Charlet A, Hoffmann LC, Eliava M, Khrulev S, Cetin AH, Osten P, Schwarz MK, Seeburg PH, Stoop R, Grinevich V. Evoked axonal oxytocin release in the central amygdala attenuates fear response. Neuron. 2012;73:553–566. doi: 10.1016/j.neuron.2011.11.030. [DOI] [PubMed] [Google Scholar]
  26. Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E. Oxytocin increases trust in humans. Nature. 2005;435:673–676. doi: 10.1038/nature03701. [DOI] [PubMed] [Google Scholar]
  27. Lischke A, Berger C, Prehn K, Heinrichs M, Herpertz SC, Domes G. Intranasal oxytocin enhances emotion recognition from dynamic facial expressions and leaves eye-gaze unaffected. Psychoneuroendocrinology. 2012;37:475–481. doi: 10.1016/j.psyneuen.2011.07.015. [DOI] [PubMed] [Google Scholar]
  28. Lynn SK, Zhang X, Barrett LF. Affective state influences perception by affecting decision parameters underlying bias and sensitivity. Emotion. 2012;12:726–736. doi: 10.1037/a0026765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Macmillan NA, Creelman CD. Detection Theory: A User’s Guide. Cambridge University Press; New York: 1991. [Google Scholar]
  30. Marsh A, Yu H, Pine D, Blair R. Oxytocin improves specific recognition of positive facial expressions. Psychopharmacology. 2010;209:225–232. doi: 10.1007/s00213-010-1780-4. [DOI] [PubMed] [Google Scholar]
  31. Mikolajczak M, Gross JJ, Lane A, Corneille O, de Timary P, Luminet O. Oxytocin makes people trusting, not gullible. Psychological Science. 2010;21:1072–1074. doi: 10.1177/0956797610377343. [DOI] [PubMed] [Google Scholar]
  32. Petrovic P, Kalisch R, Singer T, Dolan RJ. Oxytocin attenuates affective evaluations of conditioned faces and amygdala activity. The Journal of Neuroscience. 2008;28:6607–6615. doi: 10.1523/JNEUROSCI.4572-07.2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Pollak SD, Kistler DJ. Early experience is associated with the development of categorical representations for facial expressions of emotion. Proceedings of the National Academy of Sciences of the United States of America. 2002;99:9072–9076. doi: 10.1073/pnas.142165999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Ring R, Malberg J, Potestio L, Ping J, Boikess S, Luo B, Schechter L, Rizzo S, Rahman Z, Rosenzweig-Lipson S. Anxiolytic-like activity of oxytocin in male mice: behavioral and autonomic evidence, therapeutic implications. Psychopharmacology. 2006;185:218–225. doi: 10.1007/s00213-005-0293-z. [DOI] [PubMed] [Google Scholar]
  35. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan PT, Kornstein S, Manber R, Thase ME, Kocsis JH, Keller MB. The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biological Psychiatry. 2003;54:573–583. doi: 10.1016/s0006-3223(02)01866-8. [DOI] [PubMed] [Google Scholar]
  36. Russell JA, Weiss A, Mendelsohn GA. Affect grid: a single-item scale of pleasure and arousal. Journal of Personality and Social Psychology. 1989;57:493–502. [Google Scholar]
  37. Shahrestani S, Kemp AH, Guastella AJ. The impact of a single administration of intranasal oxytocin on the recognition of basic emotions in humans: a meta-analysis. Neuropsychopharmacology. 2013;38:1929–1936. doi: 10.1038/npp.2013.86. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Singer T, Snozzi R, Bird G, Petrovic P, Silani G, Heinrichs M, Dolan RJ. Effects of oxytocin and prosocial behavior on brain responses to direct and vicariously experienced pain. Emotion. 2008;8:781–791. doi: 10.1037/a0014195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Spielberger CD, Gorsuch RW, Luschene RE. State Trait Anxiety Inventory. Consulting Psychologists Press; Palo Alto: 1970. [Google Scholar]
  40. Van IJzendoorn MH, Bakermans-Kranenburg MJ. A sniff of trust: meta-analysis of the effects of intranasal oxytocin administration on face recognition, trust to in-group, and trust to out-group. Psychoneuroendocrinology. 2012;37:438–443. doi: 10.1016/j.psyneuen.2011.07.008. [DOI] [PubMed] [Google Scholar]
  41. Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. Journal of Personality and Social Psychology. 1988;54:1063–1070. doi: 10.1037//0022-3514.54.6.1063. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

01

RESOURCES